Luzhu Biotech

MedPath’s LZ901 vaccine shows **91.6% efficacy** against herpes zoster in a Phase III trial involving **26,018 adults aged 40 or older**. The recombinant gE-Fc fusion protein subunit vaccine meets a critical unmet need for older populations at higher risk of shingles. Results are published in *Nature Communications*, validating its potential as a next-generation shingles prevention tool.

Aug 2026MedPath TrialNews article

Luzhu Biotechnology’s recombinant herpes zoster vaccine **LZ901 completes Phase II trials in China**, showing stronger immune responses than placebo in 450 participants aged 50–70. The vaccine maintains a strong safety profile during testing. Luzhu now progresses LZ901 toward later-stage development.

Aug 2025MedPath TrialNews article

Beijing Luzhu Biotechnology reports positive immunogenicity and safety results for its **LZ901** vaccine in adults aged 50 or older. A randomized trial compared LZ901 head-to-head with **Shingrix (HZ/su)**, a recombinant glycoprotein E subunit vaccine, enrolling 301 participants. At least 291 received two doses of either vaccine, demonstrating efficacy in the study.

Aug 2025MarketScreenerNews article

Luzhu Biotech secures regulatory acceptance in China for its recombinant herpes zoster vaccine, **LZ901**. The National Medical Products Administration (NMPA) accepts the biologics license application, marking a key step toward potential approval. The vaccine targets the prevention of herpes zoster, a viral infection causing shingles.

Feb 2025MedPath TrialNews article